These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16710041)

  • 21. Dosing study seen as victory for clinical trials, mathematical models.
    Tuma RS
    J Natl Cancer Inst; 2003 Feb; 95(4):254-5. PubMed ID: 12591976
    [No Abstract]   [Full Text] [Related]  

  • 22. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Persistent granulocytosis and hyperuricemia after a single G-CSF injection (Filgrastim) in treatment of chemotherapy-induced myelosuppression in metastatic breast carcinoma].
    Hofmann M; Mahlke M; Casper F; Brockerhoff P
    Zentralbl Gynakol; 1995; 117(6):314-6. PubMed ID: 7544054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prevention of neutropenia during adjuvant taxotere therapy for breast cancer].
    Mochalova AS; Koroleva IA
    Vopr Onkol; 2012; 58(6):813-6. PubMed ID: 23600309
    [No Abstract]   [Full Text] [Related]  

  • 25. Pegfilgrastim: the promise of pegylation fulfilled.
    Crawford J
    Ann Oncol; 2003 Jan; 14(1):6-7. PubMed ID: 12488286
    [No Abstract]   [Full Text] [Related]  

  • 26. Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.
    Ribas A; Albanell J; Bellmunt J; Solé-Calvo LA; Bermejo B; Gallardo E; Vidal R; Vera R; Eres N; Carulla J; Baselga J
    J Clin Oncol; 1996 May; 14(5):1573-80. PubMed ID: 8622074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Toxicity of doxorubicin and cyclophosphamide (60 mg/600 mg/m2) in adjuvant chemotherapy for breast cancer].
    Tsutani Y; Saeki T; Aogi K; Ohsumi S; Takashima S
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):809-13. PubMed ID: 15984521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth factor allows effective dose-intensive regimen in advanced breast cancer patients.
    Oncology (Williston Park); 1995 Jul; 9(7):684. PubMed ID: 8924381
    [No Abstract]   [Full Text] [Related]  

  • 31. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
    Valero V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
    von Minckwitz G; Raab G; Caputo A; Schütte M; Hilfrich J; Blohmer JU; Gerber B; Costa SD; Merkle E; Eidtmann H; Lampe D; Jackisch C; du Bois A; Kaufmann M
    J Clin Oncol; 2005 Apr; 23(12):2676-85. PubMed ID: 15837982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.
    Calip GS; Malmgren JA; Lee WJ; Schwartz SM; Kaplan HG
    Breast Cancer Res Treat; 2015 Nov; 154(1):133-43. PubMed ID: 26450505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma.
    Kubo K; Miyazaki Y; Murayama T; Shimazaki R; Usui N; Urabe A; Hotta T; Tamura K
    Br J Haematol; 2016 Aug; 174(4):563-70. PubMed ID: 27072050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myeloid growth factor support for dose-dense adjuvant chemotherapy for breast cancer.
    Burstein HJ
    Oncology (Williston Park); 2006 Dec; 20(14 Suppl 9):13-5. PubMed ID: 17370924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An unusual cause of a marked leukocytosis and an abnormal blood film.
    Hargreaves T; Varey M; Kataria U; Renton B
    Br J Hosp Med (Lond); 2015 Mar; 76(3):174-5. PubMed ID: 25761812
    [No Abstract]   [Full Text] [Related]  

  • 39. Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer.
    Martin M; Vogel C; Crown J; Mackey J
    JAMA; 2005 Nov; 294(17):2166; author reply 2166-7. PubMed ID: 16264153
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparison of Doctors' and Breast Cancer Patients' Perceptions of Docetaxel, Epirubicin, and Cyclophosphamide (TEC) Toxicity.
    Bayo J; Prieto B; Rivera F
    Breast J; 2016 May; 22(3):293-302. PubMed ID: 26864346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.